VA
CORT icon

Vident Advisory’s Corcept Therapeutics CORT Stock Holding History

Vident Advisory’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$899K Sell
10,338
-2,164
-17% -$131K 0.01% 1035
2026
Q1 		$504K Sell
12,502
-2,309
-16% -$86.3K ﹤0.01% 1254
2025
Q4 		$515K Sell
14,811
-2,114
-12% -$166K ﹤0.01% 1151
2025
Q3 		$1.41M Sell
16,925
-2,971
-15% -$215K 0.01% 684
2025
Q2 		$1.46M Sell
19,896
-44,698
-69% -$3.24M 0.02% 611
2025
Q1 		$7.38M Sell
64,594
-45,184
-41% -$2.75M 0.11% 177
2024
Q4 		$5.53M Sell
109,778
-6,114
-5% -$320K 0.1% 194
2024
Q3 		$5.36M Sell
115,892
-70,128
-38% -$2.49M 0.14% 146
2024
Q2 		$6.04M Buy
186,020
+3,601
+2% +$98.6K 0.17% 120
2024
Q1 		$4.6M Buy
182,419
+94,266
+107% +$2.23M 0.1% 221
2023
Q4 		$2.86M Sell
88,153
-40
-0% -$1.1K 0.07% 296
2023
Q3 		$2.4M Buy
+88,193
New +$2.55M 0.07% 279

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vident Advisory's CORT Position: Q2 2026 in Review

Vident Advisory reduced its Corcept Therapeutics (CORT) stake by 17% in Q2 2026, selling an estimated $131K and leaving 10,338 shares worth $899K. The position accounts for 0.01% of the portfolio, ranked #1035.

Vident Advisory first reported a position in CORT in Q3 2023 and has held it in 12 quarters since. The position peaked at $7.38M in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Vident Advisory held 10,338 shares of Corcept Therapeutics worth $899K as of Q2 2026.
  • Vident Advisory sold 2,164 Corcept Therapeutics shares in Q2 2026, an estimated $131K.
  • Corcept Therapeutics made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #1035 holding.
  • Vident Advisory first reported a position in Corcept Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Vident Advisory's Corcept Therapeutics position peaked at $7.38M in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.